Dexcom's CEO, Kevin Sayer, announces his departure from the company.
In a significant move for the diabetes technology industry, Jake Leach, a 21-year veteran of Dexcom, has been appointed as the company's new CEO, effective January 1, 2026. Leach has been instrumental in the development of Dexcom's continuous glucose monitor (CGM) technology, leading teams responsible for multiple generations of CGMs, including the current G7 and over-the-counter Stelo devices.
Leach's tenure at Dexcom has seen him rise through the ranks, serving as chief technology officer from 2018 to 2022, president from May 2025, and most recently, as chief operating officer from late 2022. His extensive experience and deep technical expertise make him well-positioned to lead Dexcom's ongoing innovation and global expansion efforts.
Leach's vision for Dexcom is centred on advancing global access to diabetes monitoring technology, empowering better metabolic health worldwide, and driving innovation through an exciting product portfolio. This vision is particularly relevant as Dexcom prepares to launch an updated G7 sensor with a longer 15-day lifespan.
Outgoing CEO Kevin Sayer expressed strong confidence in Leach's ability to continue Dexcom's momentum and capitalize on future growth opportunities, particularly in expanding access and innovation in diabetes care. Sayer will remain executive chairman of Dexcom's board of directors after stepping down as CEO, aiming to set up the new leadership for success.
Leach has highlighted continued innovation as a priority, with a focus on user-beneficial features as Dexcom reaches a broader audience. This focus is evident in Dexcom's recent collaboration with Abbott, which launched the first over-the-counter glucose sensors last year.
As Leach takes the reins, he will join Dexcom's board of directors, further strengthening his role in shaping the future of the company. His impact on Dexcom moving forward is expected to focus on delivering innovative, accessible diabetes monitoring solutions worldwide.
[1] Dexcom Press Release: Jake Leach Named CEO of Dexcom, Succeeding Kevin Sayer [2] FierceBiotech: Dexcom names Jake Leach as new CEO, Kevin Sayer to become executive chairman [3] Endocrine Today: Dexcom names Jake Leach as new CEO [4] MedTech Dive: Dexcom names Jake Leach as new CEO, Kevin Sayer to become executive chairman [5] DiabetesMine: Dexcom Names Jake Leach as New CEO, Kevin Sayer to Become Executive Chairman
- The diabetes technology industry will witness significant strides under the leadership of Jake Leach, who has been appointed as the new CEO of Dexcom, effective January 1, 2026.
- Leach's role at Dexcom extends back to 21 years, during which he spearheaded the development of multiple generations of continuous glucose monitor (CGM) devices, including the current G7 and over-the-counter Stelo devices.
- In the wake of this transition, Leach is anticipated to focus on driving innovation, global expansion, and better health-and-wellness outcomes for people with diabetes.
- A strategic step towards this goal is the upcoming launch of an updated G7 sensor with a longer 15-day lifespan, further revolutionizing the medtech industry.
- Leach has emphasized the importance of AI analytics in medical-conditions management and has recently championed a cooperation with Abbott to launch over-the-counter glucose sensors, marking a milestone in AI and medtech innovation.
- As Leach embarks on this journey, his influence will extend beyond operational roles, where he will also contribute to Dexcom's strategic decisions and financial investments, pressing towards a healthier and more interconnected world.
